entertainment -WSS

entertainment

author：explore 2025-10-01 23:00:38 - browse：57

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Readout LOUD podcast: mifepristone case, GLP

Wikipedia

WSS

Scientists boost immune system in aging mice by making it youthful

Primary care physicians play key roles in Alzheimer's management

Blinken talks high

Superbugs, antibiotic resistance get scrutiny in congress

The Readout: Lenmeldy, GLP

A Greenpeace activist is fined for crash

focus

entertainment

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

BioMarin wins approval for gene therapy to treat hemophilia A

Scientists boost immune system in aging mice by making it youthful

Jerome Adams on the need for new antivirals for Covid

Oprah kicked off a national conversation on obesity. Let's have it

As demand for Covid shots wanes, Moderna seeks its next success

There's no autism epidemic. It's an autism diagnosis epidemic

United colonoscopy coverage change 'may cost lives,' doctors say

One Duchenne patient's bittersweet hope for new treatment

focus

Readout LOUD podcast: mifepristone case, GLP

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Food as medicine: Medically tailored meals may get standardized

Supreme Court mifepristone arguments center on docs' right to sue

Supreme Court mifepristone arguments center on docs' right to sue

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Wikipedia

Wikipedia

focus

hotspot